Clearside Biomedical Inc
NASDAQ:CLSD
Balance Sheet
Balance Sheet Decomposition
Clearside Biomedical Inc
Clearside Biomedical Inc
Balance Sheet
Clearside Biomedical Inc
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
2
|
8
|
20
|
35
|
9
|
8
|
23
|
17
|
30
|
48
|
29
|
20
|
|
| Cash Equivalents |
2
|
8
|
20
|
35
|
9
|
8
|
23
|
17
|
30
|
48
|
29
|
20
|
|
| Short-Term Investments |
0
|
0
|
0
|
49
|
28
|
33
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
0
|
0
|
1
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
0
|
0
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
1
|
2
|
2
|
3
|
1
|
2
|
1
|
1
|
1
|
|
| Total Current Assets |
2
|
8
|
20
|
84
|
39
|
43
|
25
|
18
|
42
|
49
|
30
|
21
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
2
|
4
|
4
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
2
|
4
|
4
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Other Long-Term Assets |
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
2
N/A
|
10
+381%
|
21
+104%
|
85
+303%
|
40
-52%
|
44
+9%
|
27
-39%
|
19
-28%
|
43
+122%
|
51
+20%
|
34
-34%
|
25
-26%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
0
|
1
|
1
|
3
|
5
|
7
|
1
|
2
|
1
|
1
|
2
|
1
|
|
| Accrued Liabilities |
0
|
1
|
2
|
3
|
5
|
3
|
3
|
2
|
4
|
5
|
5
|
3
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
2
|
0
|
3
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
5
|
5
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
1
|
2
|
5
|
5
|
14
|
10
|
11
|
10
|
5
|
6
|
7
|
5
|
|
| Long-Term Debt |
0
|
0
|
4
|
8
|
5
|
9
|
4
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
1
|
0
|
1
|
1
|
1
|
1
|
0
|
35
|
43
|
59
|
|
| Total Liabilities |
1
N/A
|
3
+168%
|
10
+288%
|
13
+26%
|
19
+45%
|
21
+7%
|
16
-24%
|
11
-32%
|
5
-53%
|
41
+726%
|
50
+23%
|
64
+28%
|
|
| Equity | |||||||||||||
| Common Stock |
12
|
27
|
47
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
12
|
22
|
39
|
65
|
124
|
207
|
238
|
256
|
255
|
288
|
321
|
355
|
|
| Additional Paid In Capital |
1
|
3
|
3
|
137
|
146
|
230
|
249
|
265
|
293
|
299
|
305
|
316
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
1
N/A
|
8
+574%
|
11
+40%
|
72
+572%
|
21
-70%
|
24
+10%
|
11
-53%
|
9
-22%
|
38
+334%
|
11
-72%
|
16
N/A
|
39
-144%
|
|
| Total Liabilities & Equity |
2
N/A
|
10
+381%
|
21
+104%
|
85
+303%
|
40
-52%
|
44
+9%
|
27
-39%
|
19
-28%
|
43
+122%
|
51
+20%
|
34
-34%
|
25
-26%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
2
|
2
|
2
|
3
|
3
|
4
|
4
|
4
|
5
|
|